163 related articles for article (PubMed ID: 33023963)
1. Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'.
Bredemeier M
Ann Rheum Dis; 2022 Dec; 81(12):e250. PubMed ID: 33023963
[No Abstract] [Full Text] [Related]
2. Response to: 'Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'' by Bredemeier.
Seibold JR; Kohlbrenner V; Alves M; Distler O
Ann Rheum Dis; 2022 Dec; 81(12):e251. PubMed ID: 33023957
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Seibold JR; Maher TM; Highland KB; Assassi S; Azuma A; Hummers LK; Costabel U; von Wangenheim U; Kohlbrenner V; Gahlemann M; Alves M; Distler O;
Ann Rheum Dis; 2020 Nov; 79(11):1478-1484. PubMed ID: 32759258
[TBL] [Abstract][Full Text] [Related]
5. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
Allanore Y; Khanna D; Smith V; Aringer M; Hoffmann-Vold AM; Kuwana M; Merkel PA; Stock C; Sambevski S; Denton CP;
Rheumatology (Oxford); 2024 Mar; 63(3):639-647. PubMed ID: 37294870
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial.
Kuwana M; Ogura T; Makino S; Homma S; Kondoh Y; Saito A; Ugai H; Gahlemann M; Takehara K; Azuma A
Mod Rheumatol; 2021 Jan; 31(1):141-150. PubMed ID: 32243207
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
Kuwana M; Azuma A
Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
[TBL] [Abstract][Full Text] [Related]
9. A new therapy for systemic sclerosis-associated interstitial lung disease.
Kondoh Y
Respir Investig; 2020 Jul; 58(4):227-229. PubMed ID: 32451295
[No Abstract] [Full Text] [Related]
10. Risk of Malnutrition in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease Treated With Nintedanib in the Randomized, Placebo-Controlled SENSCIS Trial.
Volkmann ER; McMahan ZH; Smith V; Jouneau S; Miede C; Alves M; Herrick AL;
Arthritis Care Res (Hoboken); 2023 Dec; 75(12):2501-2507. PubMed ID: 37357024
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
Azuma A; Chung L; Behera D; Chung M; Kondoh Y; Ogura T; Okamoto M; Swarnakar R; Zeng X; Zou H; Meng X; Gahlemann M; Alves M; Kuwana M;
Respir Investig; 2021 Mar; 59(2):252-259. PubMed ID: 33223487
[TBL] [Abstract][Full Text] [Related]
12. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.
Allanore Y; Vonk MC; Distler O; Azuma A; Mayes MD; Gahlemann M; James A; Kohlbrenner V; Alves M; Khanna D; Highland KB;
Ann Rheum Dis; 2022 Dec; 81(12):1722-1729. PubMed ID: 35973804
[TBL] [Abstract][Full Text] [Related]
13. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O
Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961
[TBL] [Abstract][Full Text] [Related]
14. The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease.
Wollin L; Trinh-Minh T; Zhang Y; Distler JHW
Clin Exp Rheumatol; 2021; 39 Suppl 131(4):134-141. PubMed ID: 33886452
[TBL] [Abstract][Full Text] [Related]
15. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.
Maher TM; Mayes MD; Kreuter M; Volkmann ER; Aringer M; Castellvi I; Cutolo M; Stock C; Schoof N; Alves M; Raghu G;
Arthritis Rheumatol; 2021 Apr; 73(4):671-676. PubMed ID: 33142016
[TBL] [Abstract][Full Text] [Related]
16. Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis.
Lui JK; Bosch NA; Gillmeyer KR; Reardon CC
Am J Respir Crit Care Med; 2020 Sep; 202(6):878-880. PubMed ID: 32574505
[No Abstract] [Full Text] [Related]
17. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Methodologic Considerations With Regard to a Trial of Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Comment on the Reanalysis by Maher et al.
Bredemeier M
Arthritis Rheumatol; 2021 Dec; 73(12):2353-2354. PubMed ID: 34105307
[No Abstract] [Full Text] [Related]
19. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
Yamasaki Y; Kuwana M
Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
[TBL] [Abstract][Full Text] [Related]
20. Nintedanib for systemic sclerosis-associated interstitial lung disease.
Rahimi S
Lancet Respir Med; 2020 Feb; 8(2):136. PubMed ID: 31932219
[No Abstract] [Full Text] [Related]
[Next] [New Search]
